MINNEAPOLIS--(BUSINESS WIRE)--Medtronic Inc. (NYSE: MDT) announced today the start of SYMPLICITY HTN-3, the company’s U.S. clinical trial of the Symplicity® Renal Denervation System™ for treatment-resistant hypertension. The first patient in this landmark study was enrolled at the Prairie Heart Institute at St. John’s Hospital in Springfield, Ill.
